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Abstract
Background: Endemicity of lymphatic filariasis (LF) in Cambodia was proven in 1956 when microfilariae were
detected in mosquitos in the Kratié province. In 2001, an extensive study confirmed the presence of both Brugia
malayi and Wuchereria bancrofti microfilariae. In 2003, the Ministry of Health established a national task force to
develop policies and strategies for controlling and eliminating neglected tropical diseases (NTDs), with the goal of
eliminating LF by 2015. This article summarizes the work accomplished to eliminate LF as a public health problem
in Cambodia.
Methods: The National Program to Eliminate Lymphatic Filariasis made excellent progress in the goal towards
elimination due to strong collaboration between ministries, intensive supervision by national staff, and advocacy
for mobilization of internal and external resources. Mass drug administration (MDA) with diethylcarbamazine
citrate and albendazole was conducted in six implementation units, achieving > 70% epidemiological coverage
for five consecutive rounds, from 2005 to 2009. In 2006, in 14 provinces, healthcare workers developed a line list
of lymphedema and hydrocele patients, many of whom were > 40 years old and had been affected by LF for
many years. The national program also trained healthcare workers and provincial and district staff in morbidity
management and disability prevention, and designated health centers to provide care for lymphedema and
acute attack. Two reference hospitals were designated to administer hydrocele surgery.
Results: Effectiveness of MDA was proven with transmission assessment surveys. These found that less than 1%
of school children had antigenemia in 2010, which fell to 0% in both 2013 and 2015. A separate survey in one
province in 2015 using Brugia Rapid tests to test for LF antibody found one child positive among 1677 children.
The list of chronic LF patients was most recently updated and confirmed in 2011–2012, with 32 lymphoedema
patients and 17 hydrocele patients listed. All lymphedema patients had been trained on self-management and all
hydrocele patients had been offered free surgery.
Conclusions: Due to the success of the MDA and the development of health center capacity for patient care,
along with benefits gained from socioeconomic improvements and other interventions against vector-borne
diseases and NTDs, Cambodia was validated by the World Health Organization as achieving LF elimination as a
public health problem in 2016.
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Background
Lymphatic filariasis (LF), a major public health problem
in many tropical and sub-tropical countries, is slated for
elimination as a public health problem by 2020 by the
World Health Organization (WHO). It is caused by
three species of nematode filarial worms (Wuchereria
bancrofti, Brugia malayi, and B. timori) and transmitted
by mosquitoes. Wuchereria bancrofti is the predominant
parasite and responsible for about 90% of the total LF
infections. It causes clinical conditions of lymphedema
and hydrocele, conditions that have significant social
and economic consequences [1]. Prior to the launching
of the Global Programme to Eliminate Lymphatic Filar-
iasis (GPELF) in 2000, the disease was endemic in 80
countries, 1.1 billion people were living in known en-
demic areas, and 120 million people were infected [2].
Twenty-two countries in the WHO Western Pacific Re-
gion are endemic [1].
Development of new treatment strategies and the ad-
vent of new diagnostic tools in the 1980s and 1990s pro-
vided the impetus to strive for global elimination. The
two pillars of GPELF are (a) transmission interruption
through mass drug administration (MDA) of antifilarial
drugs, and (b) alleviation of suffering in chronic patients
through morbidity management and disease prevention
(MMDP). Cambodia is among the first countries in the
world to develop and institute an LF elimination pro-
gram and successfully eliminate LF as a public health
problem.
Sociogeographic context
Cambodia is situated in Southeast Asia, bordered by the
Gulf of Thailand, Thailand, Laos, and Vietnam. As of
2015, there are an estimated 15.6 million people living in
the country, 21% of which live in urban areas [3]. The
climate is tropical. The monsoon season lasts from May
to November, and the dry season from December to
April.
Cambodia is a lower-middle-income country, with an
estimated gross national income per capita of US$ 1070
in 2015 [3]. Since 2000, Cambodia has witnessed tre-
mendous economic growth, leading to a rise in con-
sumption and a reduction in inequalities. Cambodia has
also observed a significant improvement in the health
status of the population; particularly in infant, child, and
maternal mortality, as well as a continuing decline in
HIV prevalence and deaths due to malaria [4].
Building the LF elimination program
Before the launch of the GPELF in 2000, LF had been a
low priority disease in Cambodia. In 2003, the Ministry
of Health (MoH) established a national task force for the
control of soil-transmitted helminthiases (STHs) and
schistosomiasis, and the elimination of LF (see Fig. 1).
Its major function is to develop the policies and strat-
egies for neglected tropical disease (NTD) control and
mobilization of resources. The members are drawn from
the MoH and other ministries such as the Ministries of
Education, Rural Development, and Water. Cambodia
was one of the first countries to launch programs to ad-
dress not only LF, but also two other major NTDs (STHs
and schistosomiasis) simultaneously.
The national program established immediate goals to
complete mapping of LF in the country, pilot LF MDA
in the Ratanakiri province which had historical evidence
of LF infection, and train all health personnel by 2004.
The program also established intermediate goals of 50%
LF MDA geographic coverage by 2005 and 100% by
2006, with final goals of interruption of transmission by
2010 and WHO validation of elimination by 2015.
Cambodia’s LF elimination program activities are all
coordinated by the National Center for Parasitology,
Entomology, and Malaria Control (CNM), under the dir-
ection of the national program manager. Provincial- or
district-level health officers are responsible for supervis-
ing village health workers and community members who
implement social mobilization and drug distribution
activities.
Cambodia’s LF program is an excellent example of a
lower-income country mobilizing human and financial
resources, and forging partnerships to eliminate NTDs.
Its background, implementation, and success are de-
scribed in this paper.
Methods
Delineation of endemic provinces
History of LF
The evidence for prevalence of LF first emerged in 1956.
Microfilariae were found in mosquitoes in khbal Trach
Village, Sre Cha Commune, Snuol District, Kratié Prov-
ince [5]. Studies undertaken in the 1990s provided con-
crete evidence of the species of filarial parasites
prevalent in Cambodia. In 1997, the microfilariae found
in the night blood samples of inhabitants of Tiruom
Srok Taveng Village, Taveng District, Stung Treng Prov-
ince were diagnosed as W. bancrofti [6]. In the same
year, further evidence for W. bancrofti prevalence in the
Stung Treng Province was recorded; some people sub-
jected to the immunochromatographic test (ICT), which
detects circulating filarial antigenemia of W. bancrofti, in
Sdao Village, Stung Treng District, Stung Treng Prov-
ince, showed a positive reaction [5, 7]. An extensive
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study assessed the burden of LF in northeast Cambodia
in February–April 2001, in which different LF burden
estimation techniques such as a key-informant question-
naire, clinical examination, microfilaria surveys, and
antigenemia surveys were compared. In this study, con-
ducted in the Ratanakiri Province, both B. malayi
(0.81%) and W. bancrofti (0.32%) microfilariae were
found in night blood samples of tested subjects (n = 618)
[5]. Thus, while more than one report confirms the
prevalence of W. bancrofti, the Ratanakiri study indi-
cated a co-prevalence of B. malayi and W. bancrofti.
However, there are no reports or evidence that suggest
prevalence of B. malayi in animals in Ratanakiri.
While it was recorded that both W. bancrofti and B.
malayi were prevalent in the country, no LF vector stud-
ies could be undertaken due to paucity of trained
personnel and information on the distribution of LF.
The disease was also considered of low public health im-
portance and of low priority. Hence, it is unclear as to
which species of mosquitoes are involved in the trans-
mission of LF. Cambodia has a rich fauna of Anopheles
species, some of which are involved in the transmission
of malaria [8]. Several species of Anopheles mosquitoes
are involved in the transmission of bancroftian and bru-
gian filariasis in the Southeast Asia region [9]. Involve-
ment of one or more species of Anopheles mosquitoes in
the transmission of W. bancrofti and/or B. malayi in
Cambodia may be a possibility.
The history of LF clinical disease is relatively recent in
Cambodia. A person with filarial elephantiasis was re-
ported from Stung Treng in 1995 by Medecins Sans
Frontières [6]. Subsequently, the MoH made consider-
able efforts to estimate the burden of chronic disease in
different provinces, as part of the LF mapping exercise
under the LF elimination program. In 2001, in order to
estimate the burden of LF and clinical cases, the CNM
conducted a rapid assessment using a simple question-
naire sent to three key informants in all villages of 13
provinces. The questionnaires collected the following in-
formation: 1) name and address of the key informant; 2)
five most prevalent diseases in the village; 3) presence of
individuals with swollen legs; and 4) presence of individ-
uals with swollen scrotums (for numbers 3 and 4, pic-
tures were provided along with the questionnaire).
Chronic patients were estimated based on the responses
provided by the key informants from the villages,
Fig. 1 Structure of the Cambodian MoH and national task force for the control of STHs and schistosomiasis, and the elimination of LF
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however, this method tended to overestimate the burden
of lymphedema and hydrocele patients since key infor-
mants were not medically trained in diagnosing lymph-
edema and hydrocele [5] .
Mapping
To overcome the bias of rapid assessments, the CNM
decided to implement antigenemia surveys in all 25
provinces in 2001–2002. In each province, five villages
were selected randomly from the list of all villages. In
the selected villages, the provincial health personnel with
the support of the district-level and health center staff
carried out the survey. In each village, 50 adults were
randomly selected and assessed for antigenemia using
ICTs. From the results of the surveys, four northeastern
provinces (Ratanakiri, Stung Treng, Siem Reap, and
Preah Vihear) were identified as having antigenemia-
positive individuals. In addition, a research study in
Ratanakiri, Stung Treng, Preah Vihear, and Mondulkiri
was implemented in 2001 to compare different survey
methods. In each of the 21 districts in these four prov-
inces, 3–9 villages were assessed for antigenemia and
microfilaremia prevalence, and 243 to 321 people per
district were blood tested for W. bancrofti antigene-
mia using ICTs and microfilaremia using night blood
smears [5].
On the basis of the presence of clinical cases,
microfilaria prevalence and an assessment of antigene-
mia prevalence at the province and district levels
(2000–2004), two provinces were declared entirely en-
demic, Ratanakiri and Strung Treng, and four districts
in two provinces were classified as endemic due to
the focalized nature of LF (Rovieng in Preah Vihear
province, and Varin, Angkor Chum, and Siem Reap in
Siem Reap province) (see Fig. 2). Although the antige-
nemia prevalence was < 1.0% in some districts, the
program decided to take a conservative approach and
classify any district with positive cases as endemic, as
well as implement MDA in order to eliminate infec-
tion even in low endemic foci. Based on this criter-
ion, the CNM designated both the province and
district as the implementation unit.
Implementation of the MDA program
Human resources
The CNM guided each province to build a core team of
15–20 personnel to plan and effectively implement the
MDA program. These personnel were then organized
into 4–5 teams for implementation. In order to deal with
any adverse events during the MDA and provide close
guidance and direction for drug distribution activities,
the national program manager and other CNM
Fig. 2 Map of LF endemic provinces in Cambodia
Khieu et al. Infectious Diseases of Poverty  (2018) 7:15 Page 4 of 9
personnel worked closely with drug distribution teams
and spent 2–3 months in the endemic provinces during
each round of MDA.
Training
The personnel involved in drug distribution were trained
by the CNM and provincial health department staff prior
to each round of MDA. The training focused on the
social and economic effects of LF, the objectives and ra-
tionale of the MDA program, importance of high treat-
ment coverage, and how to address adverse events due
to treatment. The numbers of personnel trained are
summarized in Table 1.
Social mobilization
The communities were informed of the drug distribution
1–2 days prior through the use of posters, loud speakers,
and leaflets. The head of the village played a key role in
ensuring the participation of the entire village. Health
personnel also played a role in social mobilization by
informing people about the risks of infection, and the so-
cial and economic impact LF can have on communities.
Drug distribution
Albendazole (ALB) was provided by GlaxoSmithKline
through the WHO donation program and diethylcar-
bamazine citrate (DEC) was procured locally by the
MoH. The provinces submitted their application for
drugs through an internal electronic system, which trig-
gered the shipping process of the requested medicine
from the central storage system to the distribution sites.
The teams disbursed the drugs from central locations,
such as pagodas, schools, and community halls. If the
people were not able to come to the central location to
receive the drug, the teams took the drugs to their
homes to impart treatment. The local healthcare
workers and other personnel involved in the drug distri-
bution were given incentives and allowances to meet the
costs of food, transportation, and accommodation. Real-
izing the benefits of the program, the health personnel
implemented the drug distribution program with a great
deal of enthusiasm and commitment.
Drug distribution was staggered, with only two imple-
mentation units conducting MDA at a time in order for
the CNM to participate in and directly observe treat-
ment in all implementation units. The teams and CNM
personnel worked with village healthcare workers and
other governmental staff such as teachers to implement
drug distribution at the community level. The teams
completed drug distribution in a cluster of villages and
then moved to the next cluster in each province. The
teams required approximately 1 month’s time to
complete drug distribution in a province. The presence
of central personnel and their participation in drug dis-
tribution activities provided good advocacy, supervision,
and goodwill for the program.
Adverse events
Incidence of adverse events was assessed within 2 hours
of implementing the MDA in 2006. Village healthcare
volunteers were asked to call the health center if a ser-
ious adverse event occurred. If an event was reported,
the health center completed the WHO serious adverse
events form, which was submitted to the team imple-
menting the MDA, and the patient suffering the adverse
event was transferred to the referral hospital.
Dizziness and nausea were the major events observed.
Mild and moderate adverse reactions were easily managed
and no serious adverse event was reported. The affected
people were advised to follow traditional treatment
methods such as drinking coconut water or tea. Medicines
were used very rarely to deal with adverse events.
Morbidity management and disease prevention (MMDP)
After establishing the MDA program in the endemic
areas, in order to achieve interruption of transmission,
the CNM turned its attention to MMDP activities, the
second pillar of the LF elimination program. In 2006, in
14 provinces, a list of patients was prepared by the
healthcare workers, who went door to door to examine
suspected patients for lymphedema or hydrocele. Forty
cases of lymphedema and 18 cases of hydrocele were
found. Most of the patients were > 40 years old and had
been affected for many years. The CNM designated the
health center as the health facility to provide services
for lymphedema and acute adenolymphangitis, or
acute attack management services, with complicated
cases referred to provincial-level health facilities. For
hydrocele surgery, given the limited capacity of hospi-
tals in the endemic districts, the program designated
two reference hospitals for surgery in Kampong Cham
and Phnom Penh.
Table 1 Training of health personnel for the LF elimination program in Cambodia
Administration
level
Training on transmission interruption Training on MMDP
Number of courses organized/ number of staff trained Number of courses organized/ number of staff trained
2006 2007 2009 2010 2007 2009 2010
Provincial 2/158 2/150 2/50 2/45 2/100 2/40 2/20
District 4/50 4/40 3/30 4/15 4/200 3/20 3/10
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Results
Program coverage
The first round of MDA was implemented in 2005 and
the target population was 434 999. In total, five rounds
of MDA were implemented consecutively from 2005 to
2009. In all implementation units, treatment coverage
exceeded the ‘effective level’ of 65% set by the WHO
during every round of MDA. The lowest average annual
coverage reported was 67% in 2005 (see Table 2).
In order to verify if the reported treatment coverage
was robust, independent treatment coverage surveys
were conducted in all implementation units after MDA
in 2006 and 2009. Those staff members from CNM and
provinces who were not associated with the LF MDA
program were drafted to conduct the coverage surveys.
These surveys were conducted following the protocol
recommended by the WHO [10]. In each implementa-
tion unit, 30 villages were sampled to assess the MDA
treatment coverage, with 10 randomly selected houses
per village sampled. Completed questionnaires were sent
to the CNM, where the data were compiled and treat-
ment coverage was calculated. The differences between
reported treatment coverage and surveyed treatment
coverage were minimal (see Table 2).
Monitoring and evaluation
Despite the relatively low baseline prevalence of LF in
the mapping sites, the country implemented a robust
monitoring and evaluation plan to monitor the progress
of the program. Two sentinel sites and two spot check
sites were selected per implementation unit. The sentinel
sites were purposefully chosen from those with the pres-
ence of either microfilariae or lymphedema or hydrocele
patients, while the spot check sites were chosen
randomly.
In each sentinel and spot check site, all the households
were listed and a sample of 60–120 households were ran-
domly selected during different surveys. All members of
the selected households aged > 5 years were assessed for
LF infection. Blood samples were collected at night be-
tween 20.00 and 23.00 h. From each person in the selected
households, two thick blood smears of 20 μl each were
collected using disposable blood lancets. The blood
smears were dried overnight and stained the next day
using Giemsa stain. The stained blood smears were exam-
ined in the village itself, allowing for the results to be im-
mediately available. In the sentinel sites, microfilaria
surveys were carried out during the baseline year (2005)
and interim years (2006, 2007, and 2008), and after the
final round of MDA (2009). In the spot check sites, the
surveys were carried out in 2007, 2008, and 2009.
The baseline microfilaria prevalence in the sentinel
sites ranged from 0.00% to 1.80% in the six imple-
mentation units. It fell to 0% in all implementation
units after two rounds of MDA. In the spot check
sites, the microfilaria prevalence was found to be 0%
in all surveys. Though the microfilaria prevalence de-
clined to 0% after two rounds of MDA, the third,
fourth, and fifth rounds of MDA were implemented
as effectively as possible, which was evident from the
high treatment coverage rates.
Stopping the MDA program
The fifth round of MDA was implemented in 2009 and
surveys to determine whether MDA could be stopped
were implemented from October to November 2010.
The CNM worked in close collaboration with the pro-
vincial health departments and provincial education de-
partment to conduct the surveys. As the WHO guidance
on administering transmission assessment surveys
(TASs) was not ready in 2010, a sampling protocol was
developed with the support of a technical expert to con-
duct the stopping MDA surveys.
The protocol advised sampling 42 schools in the six
implementation units and 900 primary school children
aged 6–10 per unit. The implementation units were di-
vided into two categories: implementation units with
relatively higher baseline microfilaria prevalence, which
also happened to be larger, i.e. provinces (Ratanakiri and
Stung Treng), and implementation units with relatively
lower microfilaria prevalence, which happened to be
smaller, i.e. districts (Siem Reap, Angkor Chum, Varin,
Table 2 Summary of national MDA data by implementation unit, by year, Cambodia
Implementation
unit
Population
(2008 census)
MDA coverage (% of the total population treated) by year
2005 2006 2007 2008 2009
Reported Reported Surveyed Reported Reported Reported Surveyed
Rovieng 35 663 76 84 77 79 78 83 82
Ratanakiri 150 466 76 79 75 86 89 81 85
Angkor Chum 53 768 73 76 77 82 81 88 86
Siem Reap 174 265 77 78 72 80 82 84 73
Varin 32 026 77 81 82 80 77 78 84
Stung Treng 111 671 67 77 73 80 80 90 74
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and Rovieng). In the former category, 27 schools were
randomly selected and in the latter category 15 schools
were randomly selected. Within the selected schools, the
required sample was obtained by using a sampling inter-
val. A few days prior to the visit of survey teams, the
provincial and district health departments informed the
selected primary schools of the survey team’s visit, dates
of activity, survey procedures, and the need to sensitize
the community and set up necessary infrastructure in
the schools. The schools extended all support to surveys:
informed parents about the survey and a ‘collective con-
sent’ was obtained from the villages’ communities. Any
parent who did not wish his/her child to be blood exam-
ined was allowed to withdraw the child from the survey.
The implementation unit was also determined to be
the evaluation unit for stopping MDA surveys and the
six implementation units were designated as six evalu-
ation units. A total of 5400 children from 42 schools in
six evaluation units were tested for W. bancrofti antige-
nemia using ICT. The number of positive children per
evaluation unit was 1–6 (see Table 3). The antigenemia
prevalence in different evaluation units ranged from
0.11% to 0.67%, below a conservative prevalence level of
< 1.00% to stop MDA. Hence, the program decided to
stop MDA in all implementation units. All children
found with antigenemia were treated with a single dose
of DEC + ALB.
Post-MDA surveillance
The post-MDA surveillance surveys were based on 2011
WHO guidance, which recommends implementation of
TASs 2–3 years (TAS 2) and 4–6 years (TAS 3) after
stopping MDA.
TAS 2 was conducted in 2013, and as the enrolment
rate exceeded 75%, school-based TAS involving children
in grades 1 and 2 was decided upon. The cluster sampling
methodology was followed and the number of schools and
children to be sampled and the sampling interval were de-
termined using the transmission assessment survey sam-
ple builder Excel tool (www.ntdsupport.org/resources).
For the purposes of TAS 2, the six implementation units
were reorganized into four evaluation units, combining
the three district implementation units of Siem Reap prov-
ince into one evaluation unit, and leaving the other three
implementation units as evaluation units. The number of
children sampled in the four evaluation units ranged from
1575 to 1805. None of the sampled children in any evalu-
ation unit was positive for antigenemia and the antigene-
mia prevalence was 0% (see Table 3).
TAS 3 was conducted in 2015, two years after TAS
2. The methodology followed for TAS 3 was similar
to that followed for TAS 2. In the four evaluation
units, 1531 to 1824 children were sampled for the as-
sessment of W. bancrofti antigen in children. A total
of 6665 children were examined in the four evalu-
ation units and all children were found to be negative
for this antigen (see Table 3).
These results suggest that the total transmission
interruption status of evaluation units, indicated by
TAS 2, continues to be sustained. In the Ratanakiri
evaluation unit, a separate TAS 3 was undertaken for
assessment of B. malayi antibody, given historical evi-
dence of B. malayi transmission [5]. In this survey,
1677 children were tested using the Brugia Rapid test
(Reszon Diagnostics, Selangor, Malaysia) with a crit-
ical cut-off of 18, and one child was found positive
(results not included in Table 3).
MMDP patient care
Lymphoedema patients were given training by health-
care workers on maintaining leg hygiene and avoiding
infections, following WHO guidance [11]. Patients
were also trained on how to cope and manage acute
adenolymphangitis episodes. They were provided with
patient self-care guides and morbidity management
kits containing soap, antibiotics, paracetamol, and
gauze cloth. These kits were provided each year
during the MDA implementation, from 2005 to 2009.
Additionally, patients were advised to buy the compo-
nents of the kits themselves, which allowed self-
treatment to continue post-MDA. These activities led
to a good rapport between the patients and healthcare
workers. Sixteen follow-up training courses were held
from 2007 to 2010 for provincial and district health
Table 3 Results of the stopping MDA surveys, and TAS 2 and TAS 3
Province Evaluation
unit
Stopping MDA surveys (2010) TAS 2 (2013) TAS 3 (2015)
Sample Positive (%) Sample Positive (%) Critical cut-off value Sample Positive (%) Critical cut- off value
Preah Vihear Rovieng 900 2 (0.22) 1750 0 16 1531 0 16
Ratanakiri Ratanakiri 900 4 (0.44) 1805 0 18 1824 0 18
Siem Reap Angkor Chum 900 1 (0.11) 1575 0 18 1728 0 18
Siem Reap 900 6 (0.67)
Varin 900 2 (0.22)
Stung Treng Stung Treng 900 3 (0.33) 1755 0 18 1582 0 18
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center staff on the role and importance of MMDP and the
methods of morbidity management, including teaching
patients self-care of lymphedema, and diagnosing and
treating acute attacks (see Table 1).
Significant efforts were also made to address the issue
of surgical intervention for hydrocele patients. No
hydrocele or other surgeries are performed in the
endemic provinces due to limited infrastructure and ex-
pertise. The program tried to convince hydrocele
patients to travel to the Kampong Cham Provincial
Hospital in Kampong Cham province or Calmette
Hospital in Phnom Penh to undergo surgery, by offering
free surgeries and support to patients’ costs of travel.
However, the patients were not willing to travel and
undergo surgeries, as they were of advanced aged and
feared post-surgery complications and long recuper-
ation time.
The list of chronic LF patients was most recently up-
dated and confirmed in 2011–2012, with 32 lymphoe-
dema and 17 hydrocele patients listed. The data suggest
that the chronic LF disease burden is not significant and
the burden over the years has been decreasing.
Discussion
Role of the government
Cambodia was able to achieve remarkable results to elim-
inate LF in the endemic provinces due to the commitment
of the government and effective implementation of MDA,
monitoring and evaluation, and surveillance activities.
Although the endemic provinces are forested and remote
areas, MDA was successfully implemented through advo-
cacy, sensitization of various departments, active partici-
pation of provincial- and central-level program personnel
in MDA activities, and financial and related support from
partners and stakeholders.
Partnership
The program built a strong partnership with inter-
national agencies with the objective of effectively
implementing the program. The major partners
include the WHO, the United States Agency for
International Development, FHI 360, RTI Inter-
national, and the Cambodia Second Health Sector
Support Program. The partners supported the pro-
gram by providing financial and technical assistance,
as well as by providing training to implement the
MDA program.
Complementary data
The four provinces endemic for LF have also been highly
endemic for malaria. Distribution of free long-lasting
insecticide nets (LLINs) began in 2000. The proportion
of the high-risk population protected with LLINs
reached 40% by 2009 and close to 100% by 2012 [8].
These nets provide protection against malaria vectors
and, to some extent, against vectors of other vector-
borne diseases, including LF. There has been a gradual
socioeconomic improvement in the provinces, as well as
a very robust MDA program against STHs in the entire
country. The STH program distributes ALB or meben-
dazole to preschool and school children, treating both
enrolled as well as non-enrolled children, and also treats
a proportion of women of childbearing age. The pro-
gram targeted 8.38 million school children in 2016, 2.71
million preschool children, and nearly four million
women of childbearing age [12]. Together, these factors
make resurgence of LF in the provinces very unlikely.
Post-validation surveillance
In 2012, the Cambodia MoH implemented a serological
survey among women aged 15–39 to assess immunity to
various diseases, including tetanus and rubella [13]. As
part of this survey, antibody responses to a variety of
parasitic infections, including W. bancrofti, were mea-
sured by multiplex bead assay. The results found
residual antibody reactivity in the North region, which
includes the LF endemic areas, and an absence of activ-
ity in non-MDA areas. Building on the success of that
research as a platform to collect LF data from through-
out the country, the program intends to implement a
post-validation surveillance system that will be inte-
grated into routine population-based surveys or ongoing
collection of other surveillance data. In 2017, with sup-
port from the WHO, the CNM will be working with the
surveillance section of the MoH to determine a sustain-
able strategy, including what type of diagnostic tests,
sampling methodology, and sample population will be
used. Sensitive diagnostic tools such as serological and
molecular tests need to be made available at the refer-
ence laboratory at the central level.
Conclusions
LF elimination dossier
In 2015, the MoH prepared its dossier documenting the
elimination of LF as a public health problem. It included
data on LF mapping in the country to determine en-
demic provinces, the establishment of the national LF
elimination program and its robust implementation of
MDA, data collected from the sentinel and spot check
sites, results from the stopping MDA surveys, as well as
a summary of post-MDA surveillance activities (TASs 2
and 3). The dossier also included information on how
the program collected the numbers of chronic LF cases
and how the health system is training, treating, and
monitoring those cases to ensure they are receiving the
care they need. The dossier was submitted for approval
to the MoH and validated by the Regional Dossier Re-
view Group of WHO’s Western Pacific Regional Office.
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In June 2016, WHO headquarters officially acknowl-
edged that elimination of as a public health problem was
achieved in Cambodia.
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